Anixa Biosciences (FRA:CY71) Cyclically Adjusted FCF per Share: €-0.24 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CY71 Anixa Biosciences Inc FRA:CY71
29 GF Score
Price €3.31
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Cyclically Adjusted FCF per Share?

Anixa Biosciences FRA:CY71 +8.72% 29 Cyclically Adjusted FCF per Share is €-0.24 as of Apr. 2026. GuruFocus rates FRA:CY71 with a GF Score™ of 29/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Anixa Biosciences's adjusted free cash flow per share for the three months ended in Apr. 2026 was €-0.044. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.24 for the trailing ten years ended in Apr. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -2.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -0.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Anixa Biosciences was 29.50% per year. The lowest was -11.60% per year. And the median was 3.30% per year.

As of today (2026-07-26), Anixa Biosciences's current stock price is €3.305. Anixa Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Apr. 2026 was €-0.24. Anixa Biosciences's Cyclically Adjusted Price-to-FCF of today is .


Anixa Biosciences  (FRA:CY71) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Anixa Biosciences Cyclically Adjusted FCF per Share Related Terms


Anixa Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Cyclically Adjusted FCF per Share Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.20 -0.34 -0.24 -0.27

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.28 -0.27 -0.26 -0.24

FRA:CY71 vs BMEA, PMN, ATRA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted Price-to-FCF falls into.


FRA:CY71
29GF Score
Anixa Biosciences Inc FRA:CY71
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anixa Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Apr. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.044/333.0200*333.0200
=-0.044

Current CPI (Apr. 2026) = 333.0200.

Anixa Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201607 -0.085 240.628 -0.118
201610 -0.071 241.729 -0.098
201701 -0.080 242.839 -0.110
201704 -0.103 244.524 -0.140
201707 -0.075 244.786 -0.102
201710 -0.041 246.663 -0.055
201801 -0.066 247.867 -0.089
201804 -0.037 250.546 -0.049
201807 -0.055 252.006 -0.073
201810 -0.048 252.885 -0.063
201901 -0.061 251.712 -0.081
201904 -0.065 255.548 -0.085
201907 -0.028 256.571 -0.036
201910 -0.060 257.346 -0.078
202001 -0.084 257.971 -0.108
202004 -0.068 256.389 -0.088
202007 -0.048 259.101 -0.062
202010 -0.050 260.388 -0.064
202101 -0.038 261.582 -0.048
202104 -0.036 267.054 -0.045
202107 -0.041 273.003 -0.050
202110 -0.030 276.589 -0.036
202201 -0.035 281.148 -0.041
202204 -0.071 289.109 -0.082
202207 -0.045 296.276 -0.051
202210 -0.053 298.012 -0.059
202301 -0.060 299.170 -0.067
202304 -0.024 303.363 -0.026
202307 -0.042 305.691 -0.046
202310 -0.060 307.671 -0.065
202401 -0.067 308.417 -0.072
202404 -0.043 313.548 -0.046
202407 -0.076 314.540 -0.080
202410 -0.026 315.664 -0.027
202501 -0.087 317.671 -0.091
202504 -0.042 320.795 -0.044
202507 -0.040 323.048 -0.041
202510 -0.033 0.000
202601 -0.067 325.252 -0.069
202604 -0.044 333.020 -0.044

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.24 mean?
Anixa Biosciences (FRA:CY71) has a Cyclically Adjusted FCF per Share of €-0.24 as of Apr. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Cyclically Adjusted FCF per Share too high?
Anixa Biosciences' current Cyclically Adjusted FCF per Share is €-0.24. Overall, Anixa Biosciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Cyclically Adjusted FCF per Share compare to BMEA and PMN?
Anixa Biosciences' Cyclically Adjusted FCF per Share of €-0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Cyclically Adjusted FCF per Share is €-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (FRA:CY71) has a current Cyclically Adjusted FCF per Share of €-0.24. The current Cyclically Adjusted FCF per Share is €-0.24. Anixa Biosciences' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Anixa Biosciences (FRA:CY71), the current Cyclically Adjusted FCF per Share is €-0.24 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges ANIX:USACY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
29GF Score

Get the complete analysis for FRA:CY71

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.31
Price